OncoResponse studies the immune systems of patients who are “elite responders” to cancer immunotherapies in order to develop new treatments for a broader array of cancer patients.
Location: United States, Washington, Seattle
Employees: 11-50
Total raised: $153.1M
Founded date: 2016
Investors 6
| Date | Name | Website |
| - | GreatPoint... | gpv.com/ |
| - | Takeda Ven... | takeda.com |
| - | Reimagined... | reimagined... |
| - | 3B Future ... | 3bfuturehe... |
| - | Canaan Par... | canaan.com |
| - | Helsinn In... | helsinninv... |
Funding Rounds 7
| Date | Series | Amount | Investors |
| 18.05.2023 | - | $27M | - |
| 31.03.2021 | Series C | $40.6M | - |
| 11.09.2018 | Series B | $40M | - |
| 09.03.2017 | Series A | $22.5M | - |
| 10.10.2016 | Series A | $7M | - |
| 10.10.2016 | - | $3.5M | Helsinn In... |
| 29.05.2016 | Series A | $12.5M | - |
Mentions in press and media 23
| Date | Title | Description |
| 18.05.2023 | OncoResponse lands $27M to advance development of antibody-based treatments for cancer | — Seattle biotech company OncoResponse landed $27 million to advance the development and testing of its antibody-based immunotherapy treatments that fight cancer. New funds will support the development of OR502 and OR2805, immunotherapy can... |
| 31.03.2021 | Seattle biotech OncoResponse raises $40.6M to create antibody-based treatments for cancer | Clifford Stocks. (OncoResponse Photo) New funding: OncoResponse raised a $40.6M Series C investment round as it continues to develop antibodies that fight cancer. The science: The company examined the immune systems of cancer patients who r... |
| 31.03.2021 | OncoResponse Raises $40.6 Million Series C Financing | - New capital will fund lead antibody, OR2805, through Phase 1 and 2 clinical studies - Adds Magnetar Group, Yonjin Ventures and Bering Capital to the syndicate SEATTLE, March 31, 2021 (GLOBE NEWSWIRE) -- OncoResponse, a biotechnology compa... |
| 31.03.2021 | OncoResponse Raises $40.6 Million Series C Financing | – New capital will fund lead antibody, OR2805, through Phase 1 and 2 clinical studies |
| 18.06.2019 | Houston’s Startups Are Now an Entrepreneurial Powerhouse | Houston is the most ethnically diverse metropolitan area in the U.S and is expected to become the third most populous U.S. city between 2025-2030. With swift growth and top talent, Houston is one of the fastest growing startup ecosystems gl... |
| 12.09.2018 | Term Sheet — Wednesday, September 12 | REBOOT REPRESENTATION Good morning, Term Sheet readers. Paid Content Securing the enterprise without boundaries From ExtraHop Melinda Gates’ Pivotal Ventures teamed up with McKinsey & Company to conduct research on tech companies’ inter... |
| 11.09.2018 | OncoResponse Grabs $40M | SEATTLE, WA, OncoResponse today announced the completion of a $40 million series B equity financing. >> Click here for more funding data on OncoResponse >> To export OncoResponse funding data to PDF and Excel, click here ... |
| 11.09.2018 | Daily funding roundup - September 11th, 2018 | Packet raises $25M to accelerate cloud growth; Syllable is raising $13.71M to healtcare providers EngageRocket: EngageRocket is a software-as-a-service platform that helps leaders and organisations make better people decisions using real-ti... |
| 11.09.2018 | OncoResponse raises $40M to start clinical trials of antibody-based cancer immunotherapies | (Bigstock Photo) OncoResponse, a Seattle biotech company creating antibody-based treatments for cancer, has raised a $40 million Series B round to advance five new treatments into preclinical and clinical trials. The company has now raised ... |
| 11.09.2018 | OncoResponse raises $40M Series B to target immunotherapy ‘elite responders’ | The company’s approach consists of tapping “elite responders,” meaning patients who have responded well to immunotherapy, and then screening their adaptive immune systems to find antibodies with exceptional reactivity, according to its webs... |
Show more